NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorKaiser Permanente
About this trial
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
Eligibility criteria
Qualifiers
Informed consent before any study-related activities.
Men or women >18 years of age who are scheduled for non-emergent cardiac surgery procedures requiring CPB and are at increased risk for surgery-related adverse cardiovascular outcomes.
CABG
Aortic, mitral, tricuspid, or pulmonic valve replacement or repair
Disqualifiers
Preexisting AKI within seven days before surgery as defined by KDIGO stage ≥1 (serum creatinine-based)
Kidney transplant status
Off-pump cardiac surgery
ESRD
Trial design
Treatments tested in this trial
- Niacinamide
- Placebo
Treatment groups
304 Participants
are divided into 2 treatment groupsSponsors and collaborators
Kaiser Permanente
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Beth Israel Deaconess Medical Center
Collaborator
Cedars-Sinai Medical Center
Collaborator
Source ClinicalTrials.gov